On Tuesday, Shares of JPMorgan Chase & Co. (NYSE:JPM), lost -4.13% to $61.45.
JPMorgan Chase & Co. will host a conference call to review fourth quarter 2015 financial results on Thursday, January 14, 2016 at 8:30 a.m. (Eastern). The results are planned to be released at 7:00 a.m. (Eastern).
JPMorgan Chase & Co. provides various financial services worldwide. The company operates through four segments: Consumer & Community Banking, Corporate & Investment Bank, Commercial Banking, and Asset Administration.
Shares of Huntington Bancshares Incorporated (NASDAQ:HBAN), declined -4.22% to $10.45, during its last trading session.
Huntington Bancshares Incorporated is upgraded by Guggenheim to Buy, according to the research report released to the investors. Earlier the firm had a rating of Neutral on the company shares. The shares recommendation by the Brokerage Firm was released on Aug-28-2015.
Huntington Bancshares Incorporated operates as a holding company for The Huntington National Bank that provides commercial, small business, consumer, and mortgage banking services.
Finally, Kythera Biopharmaceuticals, Inc. (NASDAQ:KYTH), ended its last trade with -0.05% loss, and closed at $74.68.
KYTHERA Biopharmaceuticals declared it has presented a Marketing Authorization Application (MAA) in the European Union (EU), seeking approval for ATX-101 (deoxycholic acid) injection as a treatment for the reduction of submental fat when the presence of submental fat has a psychological impact for the patient. The MAA was presented via the Decentralized Procedure with Sweden as the Reference Member State and is supported by results from four pivotal Phase III trials conducted in Europe and North America. More than 1,500 patients take partd in these trials with 757 patients treated with ATX-101.
“The submission in the European Union reflects our commitment to make ATX-101 broadly available and marks a key milestone for the global development program,” said Keith Leonard, President and Chief Executive Officer of KYTHERA. “Submental fullness, which can occur regardless of a person’s weight, is a condition that can impact both appearance and emotional well-being. We look forward to the review of our application and to the potential approval of ATX-101 in Europe as a non-surgical treatment for women and men seeking an improved chin profile.”
KYTHERA Biopharmaceuticals, Inc., a clinical-stage biopharmaceutical company, focuses on the discovery, development, and commercialization of prescription products for the aesthetic medicine market in the United States and internationally. Its product candidate ATX-101, is an injectable drug in late-stage clinical development for the the reduction of submental fat.
DISCLAIMER:
This article is published by www.wsnewspublishers.com. The Content included in this article is just for informational purposes only. All information used in this article is believed to be from reliable sources, but we make no representations or warranties of any kind, express or implied, about the completeness, accuracy, or reliability with respect to this article.
All visitors are advised to conduct their own independent research into individual stocks before making a purchase decision.
Information contained in this article contains forward-looking information within the meaning of Section 27A of the Securities Act of 1933 and Section 21E of the Securities Exchange Act of 1934, counting statements regarding the predictable continual growth of the market for the corporation’s products, the corporation’s ability to fund its capital requirement in the near term and in the long term; pricing pressures; etc.
Any statements that express or involve discussions with respect to predictions, expectations, beliefs, plans, projections, objectives, aims, assumptions, or future events or performance may be forward looking statements. Forward-looking statements are based on expectations, estimates, and projections at the time the statements are made that involve a number of risks and uncertainties, which could cause actual results or events to differ materially from those presently anticipated. Forward looking statements may be identified with such words as expects, will, anticipates, estimates, believes, or by statements indicating certain actions may, could, should/might occur.
